CoChat
Sign Up
Cited by 930Heart Failure Treatment and ManagementCardiovascular Function and Risk FactorsHeart rate and cardiovascular health

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Epidemiology and One-Year Outcomes in Patients With Chronic Heart Failure and Preserved, Mid-Range and Reduced Ejection Fraction: An Analysis of The ESC Heart Failure Long-Term Registry

Open access
Chioncel, Ovidiu, Lainscak, Mitja, Seferovic, Petar M., Anker, Stefan D., Crespo-Leiro, Maria G., Harjola, Veli-Pekka, Parissis, John, Laroche, Cecile, Piepoli, Massimo Francesco, Fonseca, Candida, Mebazaa, Alexandre, Lund, Lars, Ambrosio, Giuseppe A., Coats, Andrew J., Ferrari, Roberto, Ruschitzka, Frank, Maggioni, Aldo P., Filippatos, Gerasimos·2017·European Journal of Heart Failure
DOI 10.1002/ejhf.813
Open this paper in CoChat — free accountOpen PDF

Abstract

Aims: The objectives of the present study were to describe epidemiology and outcomes in ambulatory heart failure (HF) patients stratified by left ventricular ejection fraction (LVEF) and to identify predictors for mortality at 1 year in each group. Methods and results: The European Society of Cardiology Heart Failure Long-Term Registry is a prospective, observational study collecting epidemiological information and 1-year follow-up data in 9134 HF patients. Patients were classified according to baseline LVEF into HF with reduced EF [EF <40% (HFrEF)], mid-range EF [EF 40–50% (HFmrEF)] and preserved EF [EF >50% (HFpEF)]. In comparison with HFpEF subjects, patients with HFrEF were younger (64 years vs. 69 years), more commonly male (78% vs. 52%), more likely to have an ischaemic aetiology (49% vs. 24%) and left bundle branch block (24% vs. 9%), but less likely to have hypertension (56% vs. 67%) or atrial fibrillation (18% vs. 32%). The HFmrEF group resembled the HFrEF group in some features, including age, gender and ischaemic aetiology, but had less left ventricular and atrial dilation. Mortality at 1 year differed significantly between HFrEF and HFpEF (8.8% vs. 6.3%); HFmrEF patients experienced intermediate rates (7.6%). Age, New York Heart Association (NYHA) class III/IV status and chronic kidney disease predicted mortality in all LVEF groups. Low systolic blood pressure and high heart rate were predictors for mortality in HFrEF and HFmrEF. A lower body mass index was independently associated with mortality in HFrEF and HFpEF patients. Atrial fibrillation predicted mortality in HFpEF patients. Conclusions: Heart failure patients stratified according to different categories of LVEF represent diverse phenotypes of demography, clinical presentation, aetiology and outcomes at 1 year. Differences in predictors for mortality might improve risk stratification and management goals.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ejhf.813

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 930

Related

See all

Metadata

Authors
Chioncel, O., Lainscak, M., Seferovic, P. M., Anker, S. D., Crespo-Leiro, M. G., Harjola, V.-P., Parissis, J., Laroche, C., Piepoli, M. F., Fonseca, C., Mebazaa, A., Lund, L., Ambrosio, G. A., Coats, A. J., Ferrari, R., Ruschitzka, F., Maggioni, A. P., & Filippatos, G.
Affiliations
  • Carol Davila University of Medicine and Pharmacy (RO)
  • Department of Cardiology, General Hospital Celje
  • University of Belgrade (RS)
  • Universitätsmedizin Göttingen (DE)
  • Unidad de Insuficiencia Cardiaca Avanzada y Trasplante Cardiaco, Complexo Hospitalario Universitario A Coruna, CHUAC , LaCoruna ,
  • University of Helsinki (FI)
  • University General Hospital Attikon (GR)
  • EURObservational Research Programme, European Society of Cardiology , Sophia-Antipolis ,
  • Azienda Unità Sanitaria Locale Piacenza (IT)
  • Heart Failure Unit, S. Francisco Xavier Hospital, Centro Hospitalar Lisboa Ocidental. NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa
  • Sorbonne Paris Cité (FR)
  • Karolinska University Hospital (SE)
  • University of Perugia (IT)
  • University of Warwick (GB)
  • University of Ferrara (IT)
  • University of Zurich (CH)
  • Associazione Nazionale Medici Cardiologi Ospedalieri (IT)
  • National and Kapodistrian University of Athens (GR)
Corresponding author
Chioncel, Ovidiu
ORCID
Venue
European Journal of Heart Failure
Publisher
Oxford University Press (OUP)
Published
2017-04-06
Volume
19
Issue
12
Pages
1574-1585
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
DOI
10.1002/ejhf.813
OpenAlex
W2617287176
Cited by
927
References
29
Citations by year
2026: 76 · 2025: 115 · 2024: 139 · 2023: 134 · 2022: 118 · 2021: 107 · 2020: 89 · 2019: 65 · 2018: 68 · 2017: 15
FWCI
50.16
Type
journal article
Language
en
Open access
Licence
academic.oup.com/pages/standard-publication-reuse-rights (vor)
Locations
  • European Journal of Heart Failure (publishedVersion)
  • PubMed (publishedVersion)
  • RUC (Universidade Da Coruña) (acceptedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion)
  • Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion, other-oa)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
Funders
  • ESC
  • EURObservational Research Programme
  • Abbott Vascular Int
  • Amgen
  • Bayer Pharma AG
  • Boston Scientific International
  • Bristol Myers Squibb and Pfizer alliance
  • Boehringer Ingelheim
  • Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company
  • Menarini International Operations
  • Novartis Pharma AG
  • Merck & Co
  • Sanofi-Aventis Group
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
Keywords
chronic heart failure, left ventricular ejection fraction, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, heart failure with mildly reduced ejection fraction, one-year mortality, mortality risk factors, risk stratification, heart failure phenotypes, atrial fibrillation, chronic kidney disease, body mass index, systolic blood pressure, heart rate, left bundle branch block, NYHA functional class
MeSH terms
Aged, Cardiology, Cause of Death, Europe, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Prognosis, Prospective Studies, Registries, Severity of Illness Index, Societies, Medical, Stroke Volume, Time Factors, Incidence, Ventricular Function, Left

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review